MacroGenics reported a net income of $19.5 million for the quarter ended June 30, 2026, driven by an $89.2 million gain from discontinued operations related to the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million. Total revenue rose to $32.8 million, including a $24.5 million regulatory milestone from Sanofi and $7.3 million in royalties. The company received $10.0 million from Gilead Sciences upon the exercise of an option to license a preclinical bispecific program. MacroGenics transitioned to a fully outsourced manufacturing model with a streamlined workforce of approximately 140 employees, resulting in pro forma cash and marketable securities of $327 million and extending its cash runway through 2028. Pipeline updates include MGC026 advancing into Stage 2 for squamous cell carcinoma of the head and neck, MGD032 entering IND-enabling studies, and MGC030 receiving FDA clearance with first patient dosing expected in Q3 2026. MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for cancer.

MacroGenics, Inc. provided a clinical update on its Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate, reporting that the squamous cell carcinoma of the head and neck (SCCHN) cohort met its pre-specified response threshold in Stage 1 and is proceeding to Stage 2. As of July 8, 2026, 74 patients have been enrolled in the study, with no reported cases of dose-limiting toxicities like interstitial lung disease or ocular toxicity. MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer.

Karen Ferrante, M.D., resigned from the Board of Directors of MacroGenics, Inc. effective September 1, 2026. The resignation was for personal reasons and involved no disagreement with the company's operations, policies, or practices. MacroGenics, Inc. is a biotechnology company focused on developing and commercializing therapeutic products.

On June 30, 2026, MacroGenics, Inc. completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC. The transaction included facilities in Rockville and Frederick, Maryland, excluding research assets. MacroGenics received $122.5 million before transaction fees and expenses, subject to customary post-closing adjustments. The company operates in the biotechnology industry, focusing on the development of therapeutic antibodies.